FDA Loosens Restrictions on First-Gen CAR-T Therapies

FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers - Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

FDA loosens restrictions on first-gen CAR-T therapies

There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.

FDA drops REMS requirement for some CAR-T therapies – RamaOnHealthcare

The FDA has eliminated Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed autologous CAR-T cell immunotherapies, determining that the safety program is no longer necessary to ensure the benefits of the therapies outweigh the risks. The FDA said existing clinical experience and improved understanding of managing severe side effects, such as [...]

FDA removes hurdle to CAR T-cell therapies

The FDA is eliminating of Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed CAR T-cell therapies.